Hot off the press with the negative news surrounding Gardasil and its paralysis side effects, comes the news that another cancer vaccine, Oncophage (Antigenics), failed to demonstrate sufficient efficacy in renal cell cancer in a phase III trial.
The data was published in The Lancet online.
The accompanying editorial, from James Yang, a respected physician from the NCI, criticised the company for its over enthusiastic and misleading press releases, noting that:
"The credibility of the field of cancer immunotherapy is weakened when some investigators, and particularly vaccine companies, cannot accept the results of randomized trials."
5 months ago
No comments:
Post a Comment